Bowel Disease Drug of Pfizer Succeeds in Second Late-Stage Study

HEALTHCARE

On Tuesday, 29th March 2022, the pharmaceutical company ‘Pfizer Inc’ said that, the company’s experimental treatment for an inflammatory bowel disease, which has been acquired in 2021 as a part of the company’s 6.7 billion dollars Arena Pharmaceuticals deal has been succeeded in the second late-stage study.

Etrasimod of Pfizer has successfully showed improvement in the patients with the moderate to serious ulcerative colitis after 52 weeks, and the treatment has also met the twin main gaols of the improvement that is statistically significant in the remission at the 12th week and 52nd week as compared to placebo.

The market for the inflammatory bowel diseases across the globe has been around 20 billion dollars, which has been making it a lucrative target for the drug producers. The Ulcerative colitis, which has been a disease of the colon, has been a condition that is leading to the ulcers and also causes the abdominal pain, along with the incontinence and bloody stools.

READ  Pfizer and BioNTech Asks US Regulators To Approve 4th Covid-19 Jab For Seniors

According to the results of the first late-stage study, that has been released in past week has shown that, the once in a day drug has been responsible for improving the symptoms in the patients with ulcerative colitis at the 12th week compared to placebo.

The statistically significant improvements had also been achieved in all the main secondary goals for both the late-stage study, and Pfizer is also expecting to include the data from both the studies and also the long-term extensions of the studies.